Newsroom press releases

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)

Products Molecular

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)

Products Molecular

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)

Financial Data

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)

Products Molecular

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)

Products Molecular

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)

Financial Data

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)

Products Immunodiagnostic

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)

Products Molecular

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)

Financial Data

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)

Financial Data

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)

Products Molecular

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)

Products Molecular